Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients with Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ACCEL-001
A Phase II Randomized Trial Assessing Safety and Efficacy of Combination Reduced-dose Post-Transplant Cyclophosphamide, Tacrolimus, and Abatacept as Graft-versus-Host Disease Prophylaxis in Adults with Hematologic Malignancies undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ACCEL-002
Phase II Randomized Trial Assessing Safety and Efficacy of Combination Reduced-dose Post-Transplant Cyclophosphamide, Tacrolimus, MMF, and Ruxolitinib as Graft-versus-Host Disease Prophylaxis in Adults with Hematologic Malignancies undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Leukemia/heme